Tumor Lysis Syndrome in Pancreatic Cancer
Epidemiology and Risk Context
- The American Society of Clinical Oncology and the European Society for Medical Oncology suggest that TLS occurs predominantly in hematologic malignancies, not solid tumors, with the highest-risk malignancies being Burkitt's lymphoma and B-cell acute lymphoblastic leukemia, where TLS develops in approximately 26.4% of cases 1, 2
- The mortality rate of TLS in solid tumors approaches 35%, which is higher than in hematologic malignancies, likely due to delayed recognition and less aggressive prophylactic measures 1
High-Risk Features
- Patients with bulky disease and massive liver metastases are at high risk for TLS 1, 3
- Elevated LDH >2 times upper normal limit is a high-risk feature for TLS 4, 3
- Pre-existing renal impairment is a high-risk feature for TLS 1, 4
- Elevated baseline uric acid (>8 mg/dL in children, >10 mg/dL in adults) is a high-risk feature for TLS 4, 3
Clinical Recognition
- Hyperuricemia (>8 mg/dL in adults) from nucleic acid breakdown is a characteristic metabolic derangement of TLS 3
- Hyperkalemia causing cardiac arrhythmias, palpitations, and muscle cramps is a characteristic metabolic derangement of TLS 5
- Acute kidney injury (creatinine ≥1.5 times upper normal limit) is a characteristic metabolic derangement of TLS 3
Management Approach
- The National Comprehensive Cancer Network recommends measuring creatinine clearance or estimated GFR, serum LDH levels, baseline uric acid, potassium, phosphate, and calcium before initiating chemotherapy in pancreatic cancer patients with concerning features 3, 1
- The European Society for Medical Oncology suggests aggressive IV hydration at 3 L/m²/day to maintain urine output ≥100 mL/hour for pancreatic cancer patients with bulky disease and massive liver metastases 3
- Rasburicase 0.20 mg/kg/day IV over 30 minutes is recommended for pancreatic cancer patients with bulky disease and massive liver metastases 3